PHAR · Pharming Group N.V.
$12.62
-1.18% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$1B
Trailing P/E
68.5
Forward P/E
198.7
Dividend yield
—
Beta
0.09
Avg volume
0M
Employees
0K
2D change
3.15%
5D change
-1.19%
10D change
-3.39%
30D change
-2.45%
60D change
0.18%
MTD change
-4.71%
YTD change
-26.36%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PHAR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-04-10
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-04-10 | Canaccord Genuity | Initiates | Buy | $0.00 → $37.00 |
| 2026-03-24 | HC Wainwright & Co. | Reiterates | Buy | $37.00 |
| 2026-03-13 | Oppenheimer | Reiterates | Outperform | $42.00 → $41.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.1% below the 50-day MA ($13.13).
- Price vs 200-day MA: Trading 17.2% below the 200-day MA ($15.53).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.09) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($9.86) and high ($21.18).
PHAR Price Chart
Loading chart for PHAR…
Fundamentals
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.